Floatz logo

BMS 986156

Metastatic Carcinoma in the Liver

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Metastatic Carcinoma in the Liver cohort.

Asset / SponsorPhaseRating
INTERFERON ALFA-2B
Roswell Park Cancer Institute
Phase 2B
Dfn-15
Roswell Park Cancer Institute
Phase 2B
Nedaplatin
Zhejiang Cancer Hospital
Phase 2CCC
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 2CCC
Ipilimumab
M.D. Anderson Cancer Center
Phase 1/2CCC

View all 11 →

Same molecule, other indications

BMS 986156 is also rated in:

lung cancerDormant
CCC
Indicative ·
52 / 100
View asset →
thoracic cancerDormant
CCC
Indicative ·
52 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →